| http://www.w3.org/ns/prov#value | - Therefore sildenafil should be administered to these patients only after careful benefit-risk assessment.Vitamin K antagonistsIn pulmonary arterial hypertension patients, there may be a potential for increased risk of bleeding when sildenafil is initiated in patients already using a Vitamin K antagonist, particularly in patients with pulmonary arterial hypertension secondary to connective tissue d
|
